- Intellia Therapeutics announced third quarter 2025 financial results and provided updates on its MAGNITUDE and MAGNITUDE-2 Phase 3 trials, including the recent patient death and ongoing FDA clinical hold, with a conference call scheduled for today at 6:00 p.m. ET.
** before earnings **
** after earnings **
No comments:
Post a Comment